title: [The expediency of the clinical use of prostaglandin E2 for treating acute renal failure].
abstract: The effect of exogenous prostaglandin (PG) E2 ("PROSTENON") on the renal function and some metabolic parameters have been studied in 10 dogs with acute renal failure (ARF) caused by the crush-syndrome. It has been shown that intravenous PGE2 at a dose of 0.25 mg/kg 1 h after relief of soft tissue compression leads to prompt and stable recovery of all the renal functions under study, normalises metabolism and promotes the survival of animals. However, side effects of the drug have been revealed: blood pressure decrease and induction of vomiting effect and diarrhea. Critical analysis of the literature data has shown that, despite positive PGE2 effect on the renal function in ARF, prostenon, because of its immunosuppressive properties, cannot be used in the clinical practice for the treatment of this pathology. It is suggested that PGE2 be widely used in transplantology.
authors.forename: M P
authors.initials: MP
authors.lastname: Pavlovskiĭ
authors.forename: A N
authors.initials: AN
authors.lastname: Obornik
mesh_terms: D000818:Animals; D003444:Crush Syndrome / Q000188:drug therapy*; D015232:Dinoprostone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004285:Dogs; D007275:Injections, Intravenous; D008297:Male
chemical_list: D015232:Dinoprostone
vernacular_title: O tselesoobraznosti primeneniia prostaglandina E2 dlia lecheniia ostroĭ pochechnoĭ nedostatochnosti v klinike.